Q3 Loss Widens to 88 Cents a Share, Missing Consensus by 16 Cents
AARD sits 63% above its 52-week low of $0.93 on light trading volume (0.4× avg).
Summary
Aardvark posted an adjusted loss of 88 cents a share for the September quarter, worse than the 72-cent consensus of eleven analysts and wider than the 75-cent loss a year earlier. Revenue was zero, as expected for a pre-commercial biotech. The net loss came to $19.19 million, consistent with the 10-Q filed earlier today showing $60.3 million in cash and investments — enough to fund operations through 2027 only if the Phase 3 ARD-101 program stays paused. Research and development spending for the quarter was $15.7 million. The stock has lost 71.2% this quarter and 88.4% this year, and one analyst cut estimates in the past 30 days. The offsetting item remains the October FDA decision lifting the clinical hold on ARD-101 for Prader-Willi syndrome, with PWS trials expected in 2027, which is the real driver of the story from here.
At the time of this announcement, AARD was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.93 to $16.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.